Chemotherapy-induced nausea and vomiting in paediatric oncology
Helsinn Healthcare S.A. supports clinical research in paediatric cancer settings focused on preventing chemotherapy-induced nausea and vomiting during both single-day and multi-day high-emetogenic chemotherapy. The work centers on intravenous antiemetic regimens that combine netupitant and palonosetron, with attention to symptom control across treatment cycles in children and adolescents.
- Delayed-phase emesis
- Intravenous antiemetic therapy
- Paediatric oncology supportive care
Clinical interest extends to repeated administration, treatment tolerability, and comparison with established antiemetic combinations used in oncology care.
Pharmacokinetics and exposure assessment
The sponsor’s research includes evaluation of fosnetupitant and netupitant exposure in paediatric and adult populations, with a focus on confirming expected systemic levels after intravenous administration. This area reflects interest in how the combination product behaves across age groups and body sizes, including very young patients.
- Drug exposure
- Paediatric pharmacology
- Systemic absorption
These studies support development of antiemetic therapy with age-appropriate pharmacological performance.
Safety and tolerability of repeated treatment
Another research focus is the assessment of safety and tolerability during repeated dosing of intravenous NEPA in paediatric patients receiving chemotherapy. The clinical interest lies in maintaining control of emesis while monitoring treatment acceptability over multiple administration days.
- Repeated administration
- Tolerability assessment
- Oncology supportive treatment
This domain is closely tied to practical use in children undergoing intensive cancer therapy.
Bioequivalence of oral antiemetic formulations
Helsinn Healthcare S.A. also funds research in healthy volunteers to compare an oral suspension of the netupitant/palonosetron combination with the corresponding hard capsule formulation. The therapeutic interest is in confirming comparable performance between oral dosage forms of the same antiemetic combination.
- Oral suspension
- Hard capsule formulation
- Combination antiemetic product
This area supports formulation development for use in patients who may benefit from alternative oral delivery options.
